

CELLBANKER® 2
Cryopreservation Medium (Serum Free)
****For Research Use Only****
Manufactured By
ZENOGEN PHARMA CO., LTD.

Cat#: 11914 (100mL), 11915 (20mL)
Storage Temperature: 2 to 8°C or below -20°C
Expiry Date: 3 years from manufacturing date (see label)
Manufactured By: Zenogen Pharma Co., Ltd



Protocol:


Freezing

For optimum results, cells for cryopreservation should be in log phase of growth. Similar or other standard freezing protocols may be substituted.

1. Examine and make sure the cell culture is free of contamination, in healthy and at proper confluency.
2. Perform a cell count to determine the viability of cells.
3. Centrifuge at 1,000 - 2,000 rpm, 4°C for 3 to 5 minutes to gently pellet the cells. Remove the supernatant with an aspirator.
4. Gently suspend CELLBANKER® 2 cryopreservation medium (1 mL for 5×10^5 - 5×10^6 cells).
5. Transfer 1 mL of the cell suspension to cryopreservation vial labeled with appropriate information (the cell line name, concentration, passage date etc.).
6. Place the vials directly in -80°C for storage.
7. **(OPTIONAL)** Transfer the frozen vials to a liquid nitrogen storage tank after the vials have been frozen for at least 24 hours.

IMPORTANT: Optimum protocol may change with the cell types.

Procedure for Use:



Distributed By:



Iwai North America Inc.

URL: www.iwaichem.com
Email: orders@iwai-chem.com
Tel: 650-486-1541

Thawing

1. Remove the cryopreservation vial from the freezer and quickly thaw cells in a 37°C shaking water bath or shake by hand.
2. Transfer the content to a centrifugation tube then immediately dilute and gently mix with 10mL of complete cell culture medium. **Using CELLOTION® instead of complete culture medium will prevent adhesion of cells to the wall of the tube, increasing the recovery rate.**
3. Centrifuge cells at 1,000 - 2,000 rpm, 4°C for 3 to 5 minutes. Remove the supernatant with an aspirator.
4. Gently resuspend the cells with appropriate volume of complete cell culture medium then plate in a culture flask or plate.
5. Continue the culture procedures according to standard protocols.

Cells Tested (Check website for updated list)

Typical Experimental Results:

Cells	Preservation period	Viability of cells (%)
	(year)	preserved at -80°C
MOUSE		
Hybridome	5	90
Myeloma	5	90
L929	5	90
FM3A	5	90
BALB/3T3	5	90
RAT		
RLC-16	5	90
NKR	3	90
HAMSTER		
CHO	3	90
V79	3	90
MONKEY		
COS-1	3	90
Vero	5	90
HUMAN		
EBV transformed cell	5	90
Fibroblast	5	90
Melanoma	5	90

Distributed By:



Iwai North America Inc.

URL: www.iwaichem.com

Email: orders@iwai-chem.com

Tel: 650-486-1541

K562	5	90
Jurkat	5	90
SK-007	5	90

References:

Rimland, C. A. et al. Regional Differences in Human Biliary Tissues and Corresponding In Vitro-Derived Organoids. *Hepatology* 73, 247–267 (2021) doi: 10.1002/hep.31252.

Ogino, R., Hayashida, K., Yamakawa, S. & Morita, E. Adipose-Derived Stem Cells Promote Intussusceptive Lymphangiogenesis by Restricting Dermal Fibrosis in Irradiated Tissue of Mice. *Int J Mol Sci* 21, 3885 (2020) doi: 10.3390/ijms21113885.

Yoshimatsu, S. et al. Establishing an induced pluripotent stem cell line from neonatal common marmoset fibroblasts by an all-in-one episomal vector approach. *Stem Cell Research* 53, 102380 (2021) doi: 10.1016/j.scr.2021.102380.

Hu, Y. et al. Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week. *Nature Communications* 12, 2581 (2021) doi: 10.1038/s41467-021-22676-1.

Wei Yanxing et al. Efficient derivation of human trophoblast stem cells from primed pluripotent stem cells. *Science Advances* 7, eabf4416 doi: 10.1126/sciadv.abf4416.

Ma, L. et al. CD146 controls the quality of clinical grade mesenchymal stem cells from human dental pulp. *Stem Cell Research & Therapy* 12, 488 (2021) doi: 10.1186/s13287-021-02559-4.

Bajaj, S. et al. Neurotransmitter signaling regulates distinct phases of multimodal human interneuron migration. *The EMBO Journal* 40, e108714 (2021) doi: 10.15252/embj.2021108714.

Deng, B. et al. Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL. *Molecular Therapy - Methods & Clinical Development* 23, 633–643 (2021) doi: 10.1016/j.omtm.2021.10.006.

Ordering Details:



Iwai North America Inc.

Online: www.iwaichem.com

Email: orders@iwai-chem.com

Distributed By:



Iwai North America Inc.

URL: www.iwaichem.com

Email: orders@iwai-chem.com

Tel: 650-486-1541